Prostate Cancer

Joseph Kim, MD, discusses pivotal trials in metastatic prostate cancer, the rise of PARP inhibitors and novel combinations under investigation, and the promise of relugolix.

Daniel P. Petrylak, MD, highlights the use of abiraterone acetate, enzalutamide, and apalutamide and how these agents can lead to improvements in overall survival and progression-free survival in patients with hormone-sensitive prostate cancer.

Michael E. Hurwitz, MD, PhD, highlights the role of second-generation androgen blockers in nonmetastatic castration-resistant prostate cancer, how these agents compare, and active areas of investigation.

Michael Schweizer, MD, discusses the rationale for the phase 3 CARD trial in metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, discusses remaining challenges with abiraterone acetate in metastatic castration-sensitive prostate cancer.

Neal D. Shore, MD, FACS, discusses the approval of relugolix in advanced prostate cancer.

December 18, 2020 - The FDA has approved the oral gonadotropin-releasing hormone receptor antagonist relugolix as a treatment for patients with advanced prostate cancer.

December 17, 2020 - Androgen receptor inhibitor–therapy is associated with an increased risk of falls and fractures in patients with prostate cancer. However, since it has shown improvement in overall survival, the benefits may outweigh the risk.

Michael E. Hurwitz, MD, PhD, compares the utility of antiandrogens in nonmetastatic castration-resistant prostate cancer.

December 15, 2020 — The sequence in which hormonal therapy is given to men with localized prostate cancer should be considered as it can significantly affect outcomes.

Neeraj Agarwal, MD, remaining challenges in metastatic castration-sensitive prostate cancer.

December 10, 2020 — Despite gene expression tests helping health care professionals make optimal treatment decisions, testing varies by region for men with prostate cancer and could be related to socioeconomic status and patterns of prostate cancer care.

December 8, 2020 — Although updated guidelines and targeted therapies have led to the routine recommendation of germline genetic testing for patients with prostate cancer, increasing demand for tests and limited access to genetics providers have created an unmet need.

Michael Schweizer, MD, discusses the role of olaparib in patients with non–BRCA-mutant metastatic castration-resistant prostate cancer.

Nigerian patients with prostate cancer are noted as having higher levels of total plasma peroxide, malondialdehyde, and nitric oxide, as well as lower levels of total antioxidant capacity, even while undergoing androgen-deprivation therapy compared with Nigerian men who don't have prostate cancer.

Daniel P. Petrylak, MD, discusses the role of docetaxel based on the results of the ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Neeraj Agarwal, MD, discusses unmet needs in metastatic hormone-sensitive prostate cancer.

December 1, 2020 - The FDA has approved Gallium 68 PSMA-11, the first drug for PET imaging of prostate-specific membrane antigen–positive lesions in patients with prostate cancer.

Clinical findings have recently been reported for 2 of the more advanced emerging tubulin-targeting agents, VERU-111 and plinabulin.

Peter L. Choyke, MD, FACR, discusses recent developments in imaging for prostate cancer.

Paul C. Boutros, PhD, MBA, discusses the utility of genetic testing in prostate cancer.

Daniel W. Lin, MD, discusses the limitations of currently available biomarkers in prostate cancer.

November 23, 2020 - Patients with microsatellite instable metastatic castration-resistant prostate cancer have a distinct T-cell signature that is detectable in the peripheral blood.

Daniel W. Lin, MD, discusses the importance of biomarker research in prostate cancer.

Kirsten ​L. Greene, MD, MAS, FACS, discusse​s the future of personalized therapy in prostate cancer.